Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01719380 · ClinicalTrials.gov registry record · Phase 2
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
NCT01719380 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 156 participants.
The verdict
NCT01719380, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of LGX818 when combined with cetuximab or combined with cetuximab and BYL719 in patients with BRAF mutant metastatic colorectal cancer
Interventions
- DRUG Cetuximab
- DRUG BYL719
- DRUG LGX818
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2012-11-23 |
| Est. Completion | 2019-02-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01719380
The ClinicalTrials.gov registry entry for NCT01719380 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cetuximab is the first listed.
NCT01719380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01719380 about?
NCT01719380 is a clinical study titled "Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer". This study will assess the safety and efficacy of LGX818 when combined with cetuximab or combined with cetuximab and BYL719 in patients with BRAF mutant metastatic colorectal cancer
What is the current status of trial NCT01719380?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2012-11-23. Estimated completion is 2019-02-12.
What interventions are being tested in trial NCT01719380?
The interventions under investigation include: Cetuximab (DRUG), BYL719 (DRUG), LGX818 (DRUG).
Who is sponsoring clinical trial NCT01719380?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.